Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Notes Payables (2016 - 2020)

Zevra Therapeutics (ZVRA) has disclosed Notes Payables for 5 consecutive years, with $65.9 million as the latest value for Q3 2020.

  • For the quarter ending Q3 2020, Notes Payables rose 881.24% year-over-year to $65.9 million, compared with a TTM value of $65.9 million through Sep 2020, up 881.24%, and an annual FY2019 reading of $7.0 million, up 109.45% over the prior year.
  • Notes Payables was $65.9 million for Q3 2020 at Zevra Therapeutics, down from $67.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $68.6 million in Q1 2020 and bottomed at $3.3 million in Q1 2018.
  • Average Notes Payables over 3 years is $22.0 million, with a median of $6.5 million recorded in 2019.
  • The sharpest move saw Notes Payables surged 91.12% in 2019, then surged 977.02% in 2020.
  • Year by year, Notes Payables stood at $3.3 million in 2018, then skyrocketed by 109.45% to $7.0 million in 2019, then skyrocketed by 844.3% to $65.9 million in 2020.
  • Business Quant data shows Notes Payables for ZVRA at $65.9 million in Q3 2020, $67.3 million in Q2 2020, and $68.6 million in Q1 2020.